From Medscape Rheumatology

Coverage from the

European League Against Rheumatism (EULAR) Congress 2016

June 08 - 11, 2016; London, the United Kingdom

June 08 - 11, 2016 London, the United Kingdom
  • EULAR Single Rituximab Injection Delays RA in High-Risk Patients A single infusion of the anti-CD20 antibody rituximab, intended to deplete the B-cell population, delays the onset of rheumatoid arthritis in high-risk patients, results from the PRAIRI study suggest.
  • EULAR Anti-Interferon Antibody Curbs Lupus Disease Activity After years of clinical trial failures, early evidence suggests an anti-interferon antibody, anifrolumab, reduces disease activity in systemic lupus erythematosus, and it appears to be well tolerated.
  • EULAR Inflammatory Arthritis Stable After Switch to Biosimilar The switch to an infliximab biosimilar was not associated with any change in disease activity or worsening of flares, at least in the short term, new research shows.

Conference News

Popular News from EULAR 2015

Medscape Rheumatology©  WebMD, LLC

Previous Coverage